NurExone has created ExoTherapy, a cutting-edge exosome-based drug-delivery platform, and is currently developing its lead product, ExoPTEN, as a novel therapy for acute spinal cord injuries.   Read More >>>

The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market. This endeavor combines Inteligex’s established expertise in stem cell treatments with NurExone’s ExoTherapy drug delivery platform. Currently, NurExone is in the process of developing